Telmisartan provides better renal protection Than Valsartan in a rat model of metabolic syndrome

American Journal of Hypertension

Volumn 24, Issue 7, 2011, Pages 816-821

  Khan, Md Abdul Hye ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

blood pressure; cardiometabolic syndrome; high fat diet; hypertension; inflammation; renal injury; renin angiotensin system

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY INJURY; LIPID DIET; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; URINARY EXCRETION; WEIGHT GAIN;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY WEIGHT; DIETARY FATS; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY DISEASES; MALE; METABOLIC SYNDROME X; PPAR GAMMA; RATS; RATS, INBRED SHR; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79959372114     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.34     Document Type: Article

References (39)

1. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004; 29:31-45.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
3. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88:63-82. (Pubitemid 38165387)
4. Watson KE, Peters Harmel AL, Matson G. Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. J Cardiovasc Pharmacol Ther 2003; 8: 253-260. (Pubitemid 38045076)
5. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46:587-594. (Pubitemid 41383936)
6. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008; 51:352-359. (Pubitemid 351159950)
7. Knight SF, Yuan J, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol 2010; 298:F86-F94.
8. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17:3438-3446. (Pubitemid 44865286)
9. Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 2009; 338:301-309.
10. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesityrelated albuminuria. Obes Res 2004; 12:1278-1289. (Pubitemid 41137472)
11. Gross ML, Ritz E, Schoof A, Adamczak M, Koch A, Tulp O, Parkman A, El-Shakmak A, Szabo A, Amann K. Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 2004; 84:452-464. (Pubitemid 41656473)
12. Russo LM, Osicka TM, Brammar GC, Candido R, Jerums G, Comper WD. Renal processing of albumin in diabetes and hypertension in rats: possible role of TGF-β1. Am J Nephrol 2003; 23:61-70. (Pubitemid 36164598)
13. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003; 25:3044-3064. (Pubitemid 38096144)
14. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004; 116:31-38, 41.
15. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23:3174-3183.
16. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25:41-46. (Pubitemid 40571342)
17. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension 2004; 43:993-1002. (Pubitemid 38579904)
18. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109:2054-2057. (Pubitemid 38620211)
19. Yamagishi S, Nakamura K. Telmisartan, its potential therapeutic implications in cardiometabolic disorders. Recent Pat Cardiovasc Drug Discov 2006; 1:79-83.
20. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47:1003-1009. (Pubitemid 44297575)
21. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678. (Pubitemid 34851925)
22. Elmarakby AA, Imig JD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci 2010; 118:291-301.
23. Chung S, Park CW, Shin SJ, Lim JH, Chung HW, Youn DY, Kim HW, Kim BS, Lee JH, Kim GH, Chang YS. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant 2010; 25:389-399.
24. Shin SJ, Lim JH, Chung S, Youn DY, Chung HW, Kim HW, Lee JH, Chang YS, Park CW. Peroxisome proliferator-activated receptor-α activator fenofibrate prevents highfat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 2009; 32:835-845.
25. Saiki R, Okazaki M, Iwai S, Kumai T, Kobayashi S, Oguchi K. Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution. J Pharmacol Sci 2007; 105:157-167. (Pubitemid 350106805)
26. Tian N, Moore RS, Braddy S, Rose RA, Gu JW, Hughson MD, Manning RD Jr. Interactions between oxidative stress and inflammation in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 293:H3388-H3395. (Pubitemid 350230880)
27. Poudyal H, Panchal S, Brown L. Comparison of purple carrot juice and s-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr 2010; 104:1322-1332.
28. Yuan L, Li X, Li J, Li HL, Cheng SS. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2010; e-pub ahead of print 14 July 2010.
29. Elmarakby AA, Faulkner J, Posey SP, Sullivan JC. Induction of hemeoxygenase-1 attenuates the hypertension and renal inflammation in spontaneously hypertensive rats. Pharmacol Res 2010; 62:400-407.
30. Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010; 56:437-444.
31. Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH, Yao T, Zhu YC. Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 293:H2093-H2100. (Pubitemid 47605850)
32. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 2009; 297:F740-F748.
33. Okunuki Y, Usui Y, Nagai N, Kezuka T, Ishida S, Takeuchi M, Goto H. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Invest Ophthalmol Vis Sci 2009; 50:2255-2261.
34. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR-γ activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10: 2779-2786. (Pubitemid 39137176)
35. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94:1168-1178. (Pubitemid 38656403)
36. Dong FQ, Li H, Cai WM, Tao J, Li Q, Ruan Y, Zheng FP, Zhang Z. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J 2004; 117:1040-1044. (Pubitemid 39144892)
37. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16:638-645. (Pubitemid 41725100)
38. Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54:1353-1359.
39. Yao Y, Zou R, Liu X, Jiang J, Huang Q, He Y, Li M, Wang S, Zhou J, Ma D, Xu G. Telmisartan but not valsartan inhibits TGF-β-mediated accumulation of extracellular matrix via activation of PPAR-γ. J Huazhong Univ Sci Technol Med Sci 2008; 28:543-548.